{"id":"https://openalex.org/W2273553573","doi":"https://doi.org/10.1158/1535-7163.mct-15-0687","title":"Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers","display_name":"Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers","publication_year":2016,"publication_date":"2016-02-02","ids":{"openalex":"https://openalex.org/W2273553573","doi":"https://doi.org/10.1158/1535-7163.mct-15-0687","mag":"2273553573","pmid":"https://pubmed.ncbi.nlm.nih.gov/26839307"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-15-0687","doi":"https://doi.org/10.1158/1535-7163.mct-15-0687","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-15-0687","pdf_url":"https://aacrjournals.org/mct/article-pdf/15/5/877/1852090/877.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/mct/article-pdf/15/5/877/1852090/877.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061297807","display_name":"Kevin Hudson","orcid":"https://orcid.org/0000-0002-6608-891X","observed_orcids":["https://orcid.org/0000-0002-6608-891X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Kevin Hudson","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060775253","display_name":"Urs J. Hancox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Urs J. Hancox","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086967726","display_name":"Cath B. Trigwell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Cath Trigwell","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009167161","display_name":"Robert K. McEwen","orcid":"https://orcid.org/0009-0000-7155-5714","observed_orcids":["https://orcid.org/0009-0000-7155-5714"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert McEwen","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031229355","display_name":"Urszula M. Polanska","orcid":"https://orcid.org/0000-0003-1017-594X","observed_orcids":["https://orcid.org/0000-0003-1017-594X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Urszula M. Polanska","raw_affiliation_strings":["2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012810093","display_name":"Myria Nikolaou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Myria Nikolaou","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018957059","display_name":"Pablo Morentin Gutierrez","orcid":"https://orcid.org/0000-0003-0480-2169","observed_orcids":["https://orcid.org/0000-0003-0480-2169"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Pablo Morentin Gutierrez","raw_affiliation_strings":["2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057032447","display_name":"Alvaro Avivar\u2010Valderas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alvaro Avivar-Valderas","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022038312","display_name":"Oona Delpuech","orcid":"https://orcid.org/0009-0002-4357-498X","observed_orcids":["https://orcid.org/0009-0002-4357-498X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Oona Delpuech","raw_affiliation_strings":["2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112905353","display_name":"Phillippa Dudley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Phillippa Dudley","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023027862","display_name":"Lyndsey L. Hanson","orcid":"https://orcid.org/0000-0003-1583-7738","observed_orcids":["https://orcid.org/0000-0003-1583-7738"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lyndsey Hanson","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014622191","display_name":"Rebecca P.A. Ellston","orcid":"https://orcid.org/0000-0003-3036-190X","observed_orcids":["https://orcid.org/0000-0003-3036-190X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rebecca Ellston","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103728721","display_name":"Alys C. Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alys Jones","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027618078","display_name":"Marie Cumberbatch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Marie Cumberbatch","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013730565","display_name":"Sabina C. Cosulich","orcid":"https://orcid.org/0000-0001-9666-0510","observed_orcids":["https://orcid.org/0000-0001-9666-0510"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sabina C. Cosulich","raw_affiliation_strings":["2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2AstraZeneca Pharmaceuticals, CRUK-CI Li Ka Shing Centre, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038694709","display_name":"Lara T. Ward","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lara Ward","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074833042","display_name":"Francisco H. Cruzalegui","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Francisco Cruzalegui","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101922667","display_name":"Stephen A. Green","orcid":"https://orcid.org/0009-0000-5382-7974","observed_orcids":["https://orcid.org/0009-0000-5382-7974"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen Green","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Oncology iMed, Macclesfield, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5061297807"],"corresponding_institution_ids":["https://openalex.org/I105036370"],"apc_list":null,"apc_paid":null,"fwci":2.2455,"has_fulltext":true,"cited_by_count":41,"citation_normalized_percentile":{"value":0.88528471,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":98},"biblio":{"volume":"15","issue":"5","first_page":"877","last_page":"889"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3kalpha-inhibitor","display_name":"PI3K\u03b1 inhibitor","score":0.6259999871253967},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.8619999885559082},{"id":"https://openalex.org/keywords/pik3ca-mutation","display_name":"PIK3CA mutation","score":0.925000011920929},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.6470000147819519},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.847000002861023},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8790000081062317},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8370000123977661},{"id":"https://openalex.org/keywords/mtor","display_name":"mTOR","score":0.8399999737739563},{"id":"https://openalex.org/keywords/signaling-crosstalk","display_name":"signaling crosstalk","score":0.7730000019073486},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.7820569276809692},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6673968434333801},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.48766958713531494},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46940815448760986},{"id":"https://openalex.org/C19831878","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Therapeutic index","level":3,"score":0.46710529923439026},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.4274550676345825},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4213225543498993},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.41082507371902466},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38937807083129883},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.31408917903900146},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.2996995449066162},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.19353723526000977},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1926255226135254},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0804128646850586}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007527","descriptor_name":"Isoenzymes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010069","descriptor_name":"Oxadiazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010069","descriptor_name":"Oxadiazoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D016000","descriptor_name":"Cluster Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016923","descriptor_name":"Cell Death","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D020869","descriptor_name":"Gene Expression Profiling","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-15-0687","doi":"https://doi.org/10.1158/1535-7163.mct-15-0687","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-15-0687","pdf_url":"https://aacrjournals.org/mct/article-pdf/15/5/877/1852090/877.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:26839307","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26839307","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-15-0687","doi":"https://doi.org/10.1158/1535-7163.mct-15-0687","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-15-0687","pdf_url":"https://aacrjournals.org/mct/article-pdf/15/5/877/1852090/877.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2273553573.pdf","grobid_xml":"https://content.openalex.org/works/W2273553573.grobid-xml"},"referenced_works_count":50,"referenced_works":["https://openalex.org/W1524714842","https://openalex.org/W1873528488","https://openalex.org/W1967949926","https://openalex.org/W1975570973","https://openalex.org/W1989007214","https://openalex.org/W1992477322","https://openalex.org/W1992927742","https://openalex.org/W2009400945","https://openalex.org/W2009886463","https://openalex.org/W2014001512","https://openalex.org/W2030899725","https://openalex.org/W2033672070","https://openalex.org/W2038444072","https://openalex.org/W2042119456","https://openalex.org/W2045563337","https://openalex.org/W2054917860","https://openalex.org/W2065481080","https://openalex.org/W2076174368","https://openalex.org/W2076419931","https://openalex.org/W2083187335","https://openalex.org/W2085483616","https://openalex.org/W2092559471","https://openalex.org/W2099546337","https://openalex.org/W2101982508","https://openalex.org/W2102004296","https://openalex.org/W2117497402","https://openalex.org/W2124593509","https://openalex.org/W2125789330","https://openalex.org/W2126783165","https://openalex.org/W2129172946","https://openalex.org/W2129202918","https://openalex.org/W2137177885","https://openalex.org/W2140084692","https://openalex.org/W2144790402","https://openalex.org/W2148345265","https://openalex.org/W2150174916","https://openalex.org/W2153096480","https://openalex.org/W2154626333","https://openalex.org/W2155228605","https://openalex.org/W2164620725","https://openalex.org/W2166188515","https://openalex.org/W2168485476","https://openalex.org/W2196056082","https://openalex.org/W2275877493","https://openalex.org/W2509319388","https://openalex.org/W2562913093","https://openalex.org/W2604107344","https://openalex.org/W4301159569","https://openalex.org/W6675225945","https://openalex.org/W6684219813"],"related_works":["https://openalex.org/W2567349148","https://openalex.org/W2564369413","https://openalex.org/W2210088078","https://openalex.org/W4252786701","https://openalex.org/W2196056082","https://openalex.org/W2761960884","https://openalex.org/W2173653172","https://openalex.org/W2169450835","https://openalex.org/W2226132769","https://openalex.org/W2906255446"],"abstract_inverted_index":{"The":[0],"PIK3CA":[1,79],"gene,":[2],"encoding":[3],"the":[4,13,173,199,235],"p110\u03b1":[5],"catalytic":[6],"unit":[7],"of":[8,12,59,118,175,222],"PI3K\u03b1,":[9],"is":[10,23,55],"one":[11],"most":[14],"frequently":[15],"mutated":[16],"oncogenes":[17],"in":[18,30,49,75,83,104,153,198,206,219,238],"human":[19],"cancer.":[20],"Hence,":[21],"PI3K\u03b1":[22,60],"a":[24,43,56,184,195,220,227],"target":[25],"subject":[26],"to":[27,145,165,230,233],"intensive":[28],"efforts":[29],"identifying":[31],"inhibitors":[32],"and":[33,61,68,93,135,225],"evaluating":[34],"their":[35],"therapeutic":[36,158,236],"potential.":[37],"Here,":[38],"we":[39],"report":[40],"studies":[41],"with":[42,63,77,98,155,183,202],"novel":[44],"PI3K":[45],"inhibitor,":[46],"AZD8835,":[47],"currently":[48],"phase":[50],"I":[51],"clinical":[52,204,243],"evaluation.":[53,244],"AZD8835":[54,100,142,151,213],"potent":[57],"inhibitor":[58],"PI3K\u03b4":[62],"selectivity":[64],"versus":[65],"PI3K\u03b2,":[66],"PI3K\u03b3,":[67],"other":[69,156],"kinases":[70],"that":[71,128],"preferentially":[72],"inhibited":[73],"growth":[74],"cells":[76],"mutant":[78],"status,":[80],"such":[81],"as":[82],"estrogen":[84],"receptor-positive":[85],"(ER(+))":[86],"breast":[87,106,208],"cancer":[88,107,209],"cell":[89],"lines":[90],"BT474,":[91],"MCF7,":[92],"T47D":[94],"(sub-\u03bcmol/L":[95],"GI50s).":[96],"Consistent":[97],"this,":[99],"demonstrated":[101,203],"antitumor":[102,162,217],"efficacy":[103,218],"corresponding":[105],"xenograft":[108,148],"models":[109],"when":[110],"dosed":[111],"continuously.":[112],"In":[113,211],"addition,":[114],"an":[115],"alternative":[116,229],"approach":[117],"intermittent":[119],"high-dose":[120],"scheduling":[121],"(IHDS)":[122],"was":[123,143],"explored":[124],"given":[125],"our":[126,176],"observations":[127],"higher":[129],"exposures":[130],"achieved":[131],"greater":[132],"pathway":[133,181],"inhibition":[134],"induced":[136],"apoptosis.":[137],"Indeed,":[138],"using":[139],"IHDS,":[140],"monotherapy":[141],"able":[144],"induce":[146],"tumor":[147],"regression.":[149],"Furthermore,":[150],"IHDS":[152,214],"combination":[154,223],"targeted":[157],"agents":[159],"further":[160],"enhanced":[161],"activity":[163],"(up":[164],"92%":[166],"regression).":[167],"Combination":[168],"partners":[169],"were":[170],"prioritized":[171],"on":[172,186],"basis":[174],"mechanistic":[177],"insights":[178],"demonstrating":[179],"signaling":[180],"cross-talk,":[182],"focus":[185],"targeting":[187],"interdependent":[188],"ER":[189],"and/or":[190],"CDK4/6":[191],"pathways":[192],"or":[193],"alternatively":[194],"node":[196],"(mTOR)":[197],"PI3K-pathway,":[200],"approaches":[201],"benefit":[205],"ER(+)":[207],"patients.":[210,239],"summary,":[212],"delivers":[215],"strong":[216],"range":[221],"settings":[224],"provides":[226],"promising":[228],"continuous":[231],"dosing":[232],"optimize":[234],"index":[237],"Such":[240],"schedules":[241],"merit":[242],"Mol":[245],"Cancer":[246],"Ther;":[247],"15(5);":[248],"877-89.":[249],"\u00a92016":[250],"AACR.":[251]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":3}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}